Form 4: Alto Neuroscience Director Acquires Stock Options

Alto Neuroscience, Inc. director Andrew Dreyfus acquired stock options, as disclosed in a Form 4 filing.

Summary

• Andrew Dreyfus, a Director at Alto Neuroscience, Inc., was granted stock options on May 12, 2026.
• The options have an exercise price of $24.63 and an expiration date of May 11, 2036.
• A total of 10,958 stock options were granted.
• These options are subject to vesting conditions, with full vesting occurring on the one-year anniversary of the grant date or the Issuer's next Annual Meeting, provided continuous service is maintained.
• The options were issued under the company's Non-Employee Director Compensation Policy, meaning no direct payment was made by Dreyfus for these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation rather than a significant financial transaction or strategic shift.

Positives

• Director compensation aligns with long-term company performance through stock options.
• Granting of options indicates confidence in future stock value appreciation.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• The value of the options is contingent on future stock performance and vesting conditions.
• No immediate financial gain for the director from this transaction.

Risks

• The value of the stock options could decrease if the company's stock price falls below the exercise price.
• Vesting is dependent on continued employment, posing a risk if the director's service is terminated.
• Market volatility could impact the ultimate value of the options.

Future Outlook

The future outlook for the value of these options is tied to Alto Neuroscience's stock performance and the director's continued service, with vesting expected within one year of the grant date or by the next annual meeting.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and neuroscience sectors, aligning executive incentives with shareholder value and encouraging long-term commitment during critical growth phases.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Director Andrew Dreyfus is a related party transaction, as it involves compensation to a key insider.

Stakeholder Impact

• Shareholders: The issuance of options does not immediately dilute share count but represents potential future dilution if exercised. It aligns director incentives with long-term shareholder value.
• Employees: May view this as a positive sign of leadership commitment, but it has no direct impact on employee compensation.
• Management: Reinforces the standard compensation structure for non-employee directors.

Next Steps

• Andrew Dreyfus will continue to serve as Director.
• The stock options will vest according to the terms outlined in the Non-Employee Director Compensation Policy.
• The company's stock performance will determine the ultimate value of the options.

Key Dates

Keywords

Alto Neuroscience, ANRO, Form 4, Stock Options, Director Compensation, Insider Trading, Securities, Equity